Butyrate for IBS and Bloating: What the Research Actually Shows (2026)

By Brandon, founder of Ozzi · Published August 30, 2026

Butyrate is a short-chain fatty acid produced when gut bacteria ferment fiber, and it serves as the primary energy source for colon cells. Small human trials in patients with IBS have reported reduced abdominal pain and bloating with butyrate supplementation, though studies are limited in size and were conducted in clinical populations.

Bloating is one of those symptoms people stop mentioning because they've been told so many times it's normal. It isn't fun, and for a lot of people it's the single most frustrating part of living with a sensitive gut. You eat something reasonable. Two hours later your waistband tells a different story.

Butyrate keeps showing up in conversations about this. It's in gut health podcasts, it's on supplement labels, and it's in a growing pile of research papers. So let's go through what butyrate actually is, what the human studies have found, and where the evidence stops.

What is butyrate, and why does the gut care about it?

Butyrate is a short-chain fatty acid. Your gut bacteria produce it when they ferment fiber that your own digestive enzymes couldn't break down. It's one of three main short-chain fatty acids, alongside acetate and propionate, and it's the one the colon lining seems to care about most.

Here's the part that makes butyrate different from most nutrients. Almost everything you eat gets absorbed and shipped off to the rest of the body. Butyrate mostly stays put. The cells lining your colon, called colonocytes, take it up directly and burn it for energy. Butyrate is the primary energy source for the cells lining your colon.

That local role is why butyrate comes up in gut conversations more than the other short-chain fatty acids. If you want the full picture of the category, we wrote a complete guide to short-chain fatty acids that covers how all three are made and what each one does.

Fiber goes in, bacteria ferment it, butyrate comes out and feeds the colon lining.

What causes bloating in the first place?

Bloating is a symptom, not a diagnosis, and it has more than one cause. A few of the common ones:

• Gas from fermentation. Bacteria fermenting carbohydrates produce gas as a byproduct. Some people produce more, some clear it more slowly.
• Visceral sensitivity. Two people can have identical amounts of gas and only one feels it. The nerves reporting from the gut differ in how loudly they signal.
• Transit time. Slow movement through the colon gives fermentation more time to happen in one place.
• Bacterial distribution. When fermentation happens higher up in the small intestine than it should, the sensation tends to be worse.

Notice that only the first one is about gas volume. That distinction matters, because most over-the-counter bloating products target gas volume alone and leave the sensitivity side untouched.

Two people can have the same amount of gas and only one of them feels it.

What has the research actually studied?

This section deserves a careful read, because the butyrate research is stronger than most supplement science and weaker than the marketing around it suggests. Every study below was run in people who had been diagnosed and were under medical care. That context does not transfer automatically to a healthy person with occasional bloating.

In a randomized, double-blind, placebo-controlled trial published in Scientific Reports in 2026, researchers gave microencapsulated sodium butyrate or placebo to 52 patients who had both type 2 diabetes and met Rome IV criteria for IBS. Over 12 weeks, the butyrate group showed significant reductions in abdominal pain, diarrhea, and bloating, with bloating reaching p < 0.001. The placebo group showed no significant change. This was a human trial in a specific patient population, and it was small.

A 2025 randomized, placebo-controlled trial in the Journal of Pediatric Gastroenterology and Nutrition tested calcium butyrate in 51 children aged 4 to 17 with IBS diagnosed by Rome IV criteria. Treatment success reached 73% in the butyrate group versus 3.8% on placebo. Stool analysis showed increases in short-chain fatty acid producing bacteria including Lachnospiraceae, and a decrease in Ruminococcus gnavus, a taxon often elevated in inflammatory gut conditions. Again: human, but pediatric patients under specialist care.

A third trial, published in the Journal of Clinical Medicine, randomized 120 adults with IBS to a combination of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides, or to placebo, for 12 weeks. By week four, 64.7% of the biotic group reported adequate relief versus 42.0% on placebo. Worth flagging honestly: the trial found no significant difference in overall symptom severity scores or quality of life, which is a more mixed result than the headline suggests. It also tested a combination product, so butyrate cannot be credited alone.

The most mechanistically interesting one came out of Örebro University in Gut Microbes in 2025. Researchers ran a colonoscopy-perfusion model, delivering butyrate directly to a defined section of the descending colon in 17 IBS patients and 17 healthy controls, then testing biopsies in Ussing chambers. Butyrate exposure significantly reduced chemically induced transcellular hyperpermeability in the IBS group. That is a human study, in living tissue, showing a barrier-related effect rather than just a symptom questionnaire.

We keep the species label on every row on purpose. The gut microbiome field is full of mouse findings that get repeated as human fact, and the fastest way to lose trust is to blur that line. If you want more of our reasoning on this, we covered it in butyrate benefits, hype, and downsides.

How might butyrate affect bloating specifically?

Three plausible routes, ranked by how much human evidence sits behind each.

Barrier function. The Örebro colonoscopy study showed butyrate reducing induced permeability in human IBS tissue. In cell models, short-chain fatty acid fermentation products upregulate tight junction proteins including ZO-1, claudin-1, and occludin. Barrier integrity and bloating are linked in the research literature, though the connection is indirect. We go deeper on this in our piece on how to support gut barrier function naturally.

Bacterial composition. The pediatric trial found butyrate supplementation shifted the microbiota toward short-chain fatty acid producers and away from taxa associated with inflammation. Different fermenters produce different amounts of gas, so a shift in composition could plausibly change how much gas gets made.

Inflammatory tone. In primary rat colonocytes, butyrate protected against TNF-alpha induced cytotoxicity and preserved mitochondrial membrane potential. That's rodent work in a dish, so treat it as mechanism rather than proof. Our butyrate and inflammation post walks through what that literature does and doesn't establish.

The honest summary: promising human signal, small trials, mechanism still being worked out.

Can you just eat more fiber instead?

Partly. Your bacteria make butyrate from fermentable fiber, so feeding them is the original route. A randomized controlled trial in International Journal of Obesity gave inulin, maltodextrin placebo, or dietary fiber advice to 143 children with obesity over six months. The inulin group showed significantly increased microbial diversity and higher abundance of butyrate-producing genera including Agathobacter, Eubacterium coprostanoligenes, and Subdoligranulum. That's a human trial showing prebiotic fiber raising butyrate producers.

Chicory root, Jerusalem artichoke, asparagus, garlic and oats all feed butyrate-producing bacteria.

The catch is that fermentable fiber is also gas-forming. If bloating is your main complaint, ramping fiber quickly is a reliable way to make things worse for a few weeks before they get better. Two practical notes: go slower than feels necessary, and split doses across the day rather than taking one large serving.

There's also a plain arithmetic problem. Getting a meaningful amount of butyrate from diet alone requires a lot of fermentable fiber and a microbiome already equipped to ferment it. People with disrupted microbiomes are often the ones with the least capacity to produce butyrate and the most trouble tolerating the fiber that would fix it. We laid out the workarounds in how to increase butyrate naturally.

What forms of butyrate supplement exist?

We use L-Lysine Butyrate in Ozzi because it disperses in cold water without the odor problem that makes uncoated butyrate close to undrinkable. Being straight with you: there are no published human randomized trials on L-Lysine Butyrate specifically. The trials above used sodium and calcium forms. If you want the side-by-side, see sodium butyrate vs tributyrin and tributyrin vs lysine butyrate.

And if you've ever opened a butyrate supplement and wondered what happened, our post on why butyrate smells the way it does explains the chemistry. Butyric acid is the compound responsible for the smell of rancid butter, so the odor is just the molecule being itself rather than a manufacturing problem.

Ozzi pairs 500mg of L-Lysine Butyrate with 500mg of chicory root inulin in each stick.

Where does Ozzi fit, honestly?

Ozzi is a daily drink stick built around appetite support, and gut support is part of how it's formulated. Each stick includes 500mg of L-Lysine Butyrate plus 500mg of chicory root inulin, which is a prebiotic fiber that feeds butyrate-producing bacteria. Direct butyrate and fuel for your own production, in one glass of water.

What Ozzi is not: a treatment for IBS. If you have persistent bloating, changes in bowel habit, unexplained weight loss, blood in your stool, or symptoms that wake you at night, that's a conversation with a doctor, not a supplement decision. IBS is a diagnosis of exclusion and it deserves a real workup.

Ozzi also contains 8g of allulose, 500mg of glucomannan for viscosity and satiety, African mango, and chromium. If cravings and food noise are the bigger issue for you, our posts on how to quiet food noise and gut health and GLP-1 are the better starting point. A note on butyrate and GLP-1 specifically: the proposed link runs through L-cell stimulation and comes from cell and rodent work. No human study has shown butyrate raising GLP-1, and we'd rather say that plainly than let the mechanism drift into a claim.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is educational and is not medical advice. Talk to a healthcare provider about persistent digestive symptoms.

References

1. Panufnik P, et al. Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial. Scientific Reports. 2026. Human RCT. https://doi.org/10.1038/s41598-026-47309-9
2. Cristofori F, et al. Calcium butyrate efficacy in pediatric irritable bowel syndrome: randomized placebo-controlled multiomics-based clinical trial. Journal of Pediatric Gastroenterology and Nutrition. 2025;81(3):551-561. Human RCT. https://doi.org/10.1002/jpn3.70154
3. Gąsiorowska A, et al. Efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short chain fructooligosaccharides in patients with irritable bowel syndrome. Journal of Clinical Medicine. 2025;14(1):6. Human RCT. https://doi.org/10.3390/jcm14010006
4. Scharf MW, et al. Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model. Gut Microbes. 2025;17(1):2545414. Human clinical trial. https://doi.org/10.1080/19490976.2025.2545414
5. Souders CL, et al. Interaction between butyrate and tumor necrosis factor α in primary rat colonocytes. Biomolecules. 2023;13(2):258. Rodent, in vitro. https://doi.org/10.3390/biom13020258
6. Liu Y, et al. Anti-inflammatory and barrier-protective effects of galacto-oligosaccharides and Limosilactobacillus reuteri M94: an in vitro microbiota-based assay. Food Research International. 2026;229:118487. In vitro. https://doi.org/10.1016/j.foodres.2026.118487
7. Visuthranukul C, et al. Enhancing gut microbiota and microbial function with inulin supplementation in children with obesity. International Journal of Obesity. 2024;48(12):1696-1704. Human RCT. https://doi.org/10.1038/s41366-024-01590-8